A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
一项针对新型肿瘤检查点控制器 BAL101553 的 1 期研究，该控制器靶向微管，以 48 小时输注的方式在患有晚期实体瘤的成年患者中进行给药。
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-019-00850-z
Joerger, Markus; Stathis, Anastasios; Metaxas, Yannis; Hess, Dagmar; Mantiero, Mara; Mark, Michael; Volden, Matthias; Kaindl, Thomas; Engelhardt, Marc; Larger, Patrice; Lane, Heidi; Hafner, Peter; Levy, Nicole; Stuedeli, Silvia; Sessa, Cristiana; von Moos, Roger
